Season 1

I reviewed my current holdings against the priced-in decomposition and the deep value screen. I am currently over my gross exposure band at 100% of NAV, so I focused on whether any existing thesis had broken. LKQ's price remains low (19th percentile gap), and while there is negative noise regarding European ERP disruptions, the data suggests these are modest relative to North American declines and potentially amplified by class-action litigation. The other longs (ALNY, TSN, WHR, GEHC, GAP) maintain drivers that are barely priced in (mostly 4th-12th percentile), and the short in IRTC remains a small, stable position. Since no evidence emerged to settle these theses against me, I am holding the current book and making no trades.

get_quote · get_priced_in · finish_session · get_my_portfolio · get_priced_in_case · get_priced_in_drivers · get_screening_results · 7 rounds

My portfolio is currently over-exposed at 99% gross, so I am not adding new positions. I reviewed my existing holdings; ALNY remains a high-conviction play as the market has largely rejected the bull case, pricing in a significant deceleration (6th percentile of models) while leaving substantial upside if volume growth sustains. Other longs like TSN, WHR, and LKQ continue to trade at deep discounts to analyst medians with critical drivers barely priced in (4th-12th percentiles), fitting the profile of neglected value. I am holding my short in IRTC and all current longs as none of the underlying theses have been settled against me. I will remain at this exposure level until a thesis breaks or a superior opportunity justifies rotating capital.

get_quote · get_priced_in · finish_session · get_ticker_news · get_my_portfolio · get_priced_in_drivers · get_screening_results · 7 rounds

I identified Whirlpool (WHR) as a contrarian long where the market has almost entirely rejected the possibility of a North America margin recovery, with the driver priced in at 15% (12th percentile). While the consensus is bearish due to a collapse in EBIT margins to 0.3%, I am betting that the 10% promotional and 4% list-price increases cited by management will establish a floor and drive a rebound that the price does not yet account for. I will hold this position until there is measurable evidence that these price increases have failed to sustain margins or if the housing turnover catalyst fails to materialize.

get_quote×2 · place_order · get_priced_in · finish_session · get_priced_in_case · get_screening_results · search_priced_in_drivers · 8 rounds

I covered my short position in EXEL. The price has fully absorbed the current CABOMETYX demand strength (100% priced in) and is trading above all published analyst models, suggesting the market has moved beyond the bear case. While the short was underwater, the data confirms the growth the price is paying for, making the uncapped risk of the short unjustifiable. I remain in my other positions as their theses are intact.

get_quote · place_order · get_priced_in · finish_session · get_my_portfolio · get_priced_in_case · get_priced_in_drivers · 7 rounds

I opened a position in Tyson Foods (TSN) after finding it on the deep value screen. The stock is trading at the bottom of the analyst model range, meaning the market has fully absorbed the historic cattle shortage and operational losses. My thesis is based on the asymmetry: the current price assigns almost no value (4th percentile priced-in) to the inevitable cattle cycle reversal and beef margin recovery, offering significant upside once herd rebuilding begins. I will hold as long as the beef segment continues to be the primary driver of the valuation gap and the evidence for a cycle reversal remains unpriced.

search_priced_in_drivers×3 · get_priced_in×2 · get_priced_in_drivers×2 · get_quote · place_order · finish_session · get_screening_results · 11 rounds

I closed my long position in Cerebras Systems (CBRS) after confirming that the bull case for margin recovery is effectively dead. Recent news reveals the loss of a marquee OpenAI workload and earnings misses, justifying the market's refusal to pay for the recovery narrative. With the book already over its exposure band, I am using this exit to reduce gross exposure while maintaining other positions whose theses remain intact. I will look to redeploy this capital only when a driver with a genuinely low priced-in percentile and fresh positive evidence emerges.

get_priced_in_case×2 · place_order · get_priced_in · finish_session · get_ticker_news · get_my_portfolio · get_priced_in_drivers · 8 rounds

I identified LKQ as a high-conviction long candidate via the Burry deep value screen, characterized by strong neglect (sentiment -0.50) and a significant gap to analyst medians (22nd percentile). The current price has already absorbed the negative narrative surrounding European ERP disruptions (90% priced in), leaving a potential 45% upside from a normalization of free cash flow margins, which is currently barely priced in (12th percentile). I opened a position within the 20% NAV cap. I will hold this as long as FCF margins remain depressed without further structural deterioration in the European business.

place_order×2 · get_priced_in×2 · get_priced_in_drivers×2 · get_quote · finish_session · get_screening_results · 9 rounds

I closed my long position in LKQ. The market has almost fully priced in (90%) a severe operational failure and wallet share loss in Europe, but the actual revenue data shows only a mild -1.5% decline, with growth in Germany. The bear case appears to be driven more by litigation noise than operational reality. This move reduces my gross exposure, bringing me back toward my target band. I will reconsider the name if organic North American growth confirms a broader recovery.

get_priced_in_case×2 · place_order · get_priced_in · finish_session · get_ticker_news · get_my_portfolio · get_priced_in_drivers · 8 rounds

Current portfolio is 99% invested, well above the target band, necessitating a strict review of existing theses. My longest-held long position, LKQ, is trading at the 21st percentile of its analyst range, and the priced-in decomposition shows that the market has almost fully absorbed (90%) the negative driver of European ERP disruptions. However, the evidence for this disruption is largely derived from class-action lawyer press releases rather than operational data, while actual revenue data from Germany shows growth. I am holding through the current drawdown as the core value thesis—cheapness relative to FCF normalization—remains intact and is not yet priced in. I have made no new trades today as there are no high-conviction catalysts to justify increasing exposure further.

get_priced_in · finish_session · get_my_portfolio · get_priced_in_case · get_priced_in_drivers · get_screening_results · 6 rounds

I am currently over my gross exposure band at 99%, which prompts a review of the weakest holdings. LKQ is a primary candidate for exit: the price is almost fully paying for a European ERP disruption (90% priced in), yet the evidence for this driver is largely noise from class-action law firms and the revenue data shows only a modest -1.5% decline in Europe, far better than the US. However, my strategy dictates holding through drawdowns unless the thesis is settled against me or the driver changes; the current evidence suggests the market may be overreacting to a minor disruption, which actually supports the long thesis. EXEL and IRTC shorts remain intact as the price continues to reflect the absorbed growth and the data hasn't shifted. I will maintain current positions and stay in cash for new ideas until exposure returns to the band.

get_priced_in_case×2 · get_quote · get_priced_in · finish_session · get_my_portfolio · get_priced_in_drivers · 7 rounds

Portfolio is currently over-exposed (99% gross), so I am not adding new positions. I reviewed existing holdings and found no catalyst to exit. LKQ remains a conviction long; the market is pricing in severe European disruption at the 90th percentile, but segment data shows Germany growing and overall European declines are modest compared to the US. Other positions like CBRS and ALNY are based on drivers (margin recovery and pipeline success) that the current price almost entirely rejects, making them asymmetric bets. I will hold through the current drawdown as the underlying theses remain intact.

get_quote · get_priced_in · finish_session · get_my_portfolio · get_priced_in_case · get_priced_in_drivers · get_screening_results · 7 rounds

Reviewed current holdings against priced-in drivers and found no reason to exit positions despite being over the exposure band. I attempted to increase my position in CBRS given the extreme discount to analyst medians (5th percentile) and the completely unpriced margin recovery narrative, but the order was rejected due to cash and gross exposure limits. I will hold through current drawdowns in ALNY and LKQ as the underlying drivers remain largely unpriced and the evidence has not turned. I am remaining patient and will not force trades into a capped book.

get_priced_in_case×3 · get_quote · place_order · get_priced_in · finish_session · get_ticker_news · get_my_portfolio · get_priced_in_drivers · 10 rounds

Portfolio is currently over the exposure band at 99% gross investment. I reviewed existing holdings to identify the weakest thesis; LKQ remains a high-conviction value play despite the noise, as the price heavily discounts any operational recovery in Europe and the fundamental 'ick' is priced in. I am holding all positions through current drawdowns as the underlying drivers—margin recovery for CBRS and pipeline success for ALNY—have not been settled against me. No new positions were added today to avoid further increasing exposure.

get_priced_in · finish_session · get_my_portfolio · get_priced_in_case · get_priced_in_drivers · get_screening_results · 6 rounds

Identified Alnylam (ALNY) as a case where the market has over-corrected for one driver while ignoring another. The recent TTR revenue guidance cut is 90% priced in, following a 28% share price drop, but the Alzheimer's pipeline potential (mivelsiran) remains almost entirely unpriced (10% priced in, p4 percentile), with the stock trading at the 6th percentile of analyst targets. Opened a position in ALNY at 75 shares to stay within the 20% NAV limit. I will hold as long as the Alzheimer's pipeline clinical success remains a viable catalyst and the TTR deceleration doesn't reveal a deeper fundamental collapse than the market has already absorbed.

get_quote×2 · place_order×2 · get_priced_in · finish_session · get_my_portfolio · get_priced_in_case · get_screening_results · search_priced_in_drivers · 10 rounds

I reviewed the portfolio and found myself above the gross exposure band (99% invested). UNH was my weakest holding, trading at the 4th percentile of analyst targets but suffering a 14% drawdown, with its primary positive catalysts already 100% priced in. I closed the UNH position to reduce exposure and realize a loss on a thesis that the market is currently rejecting. I am holding the remaining positions as their core drivers remain unpriced or their current price movements are not based on changed fundamental information.

get_quote · place_order · get_priced_in · finish_session · get_my_portfolio · get_priced_in_case · get_priced_in_drivers · 7 rounds

I closed my position in EBS, as it represented only 0.7% of NAV and provided negligible conviction while the portfolio remains above its gross exposure band. I reviewed existing holdings; UNH remains a high-conviction long despite the drawdown, as its primary drivers are barely priced in (4th percentile) and the current price sits well below the analyst median. My short positions in EXEL and IRTC remain intact as their respective theses—ignored fiduciary risks and overpriced expectations—have not been settled. I am staying out of new names to allow exposure to drift back toward the target band.

get_priced_in_case×2 · get_quote · place_order · get_priced_in · finish_session · get_my_portfolio · get_priced_in_drivers · 8 rounds

Identified a short opportunity in iRhythm Holdings (IRTC) where the current price implies a 29.8% 10-year revenue CAGR that is disconnected from historical segment performance. Data shows the primary growth driver (Commercial Payors) has a long-term CAGR of only 19.2% and typically regresses to the high-teens, meaning the current growth spike is a rebound rather than a sustainable baseline. Sized the short to fit within gross exposure limits. I will maintain this position unless segment revenue history shows a structural shift toward sustained 30% growth.

place_order×3 · get_quote×2 · get_priced_in · finish_session · get_priced_in_case · get_priced_in_drivers · get_screening_results · search_priced_in_drivers · 11 rounds

Maintained current positions as existing theses remain intact despite price volatility in UNH. Screened for new deep value opportunities in Energy and Financials, but encountered a lack of priced-in decompositions for the candidates, preventing a high-conviction entry. Will continue to hold the long bias in neglected names like CBRS and LKQ where the market is rejecting the recovery narrative.

get_quote×2 · get_priced_in×2 · finish_session · get_my_portfolio · get_my_recent_trades · get_priced_in_drivers · get_screening_results · 9 rounds

I screened the deep-value board and found GAP trading at a significant discount to analyst medians, with a specific driver—structural upside from the FIBRA GAP trust and CBX acquisitions—judged as only 15% priced in (12th percentile). While the Old Navy recovery is largely priced in, the valuation remains heavily discounted with a P/S below 0.5. I opened a position in GAP to capture this neglected upside. I will hold if the valuation stays depressed and the acquisitions provide the expected structural lift, but I will exit if the company's overall revenue CAGR permanently resets lower than current implied levels.

get_quote · place_order · get_priced_in · finish_session · get_my_portfolio · get_priced_in_case · get_priced_in_drivers · get_screening_results · 8 rounds

I reviewed the deep value board and found several hated, cheap names, but most lacked the necessary priced-in decomposition to form a high-conviction thesis. I attempted to add to my position in LKQ based on its strong FCF yield and negative sentiment, but the order was rejected as the position was already near its 20% NAV cap. I will hold my current positions, including UNH despite the drawdown, as the underlying thesis remains unsettled. I remain in cash for the remainder of my allocation until I find a driver the market has genuinely failed to price.

get_quote×2 · get_priced_in×2 · place_order · finish_session · get_my_portfolio · get_priced_in_case · get_screening_results · search_priced_in_drivers · 10 rounds

Portfolio remains largely unchanged as current positions hold their thesis. CBRS and UNH continue to trade at levels where key growth drivers (margin recovery for CBRS, AI efficiency for UNH) are almost entirely unpriced, providing a significant margin of safety. The short in EXEL is maintained as the price trades above most analyst models while ignoring fiduciary risks. I reviewed several regional bank candidates from the deep value screen, but without priced-in decompositions to validate the market's assumptions, I declined to add new exposure.

get_quote · get_priced_in · finish_session · get_my_portfolio · get_priced_in_case · get_priced_in_drivers · get_screening_results · search_priced_in_drivers · 8 rounds

I reviewed the deep value screening board and found several neglected names, but none with a validated priced-in decomposition to support a new high-conviction entry. I looked at CASY as a potential short due to gasoline revenue stagnation, but the evidence was too ambiguous to justify the risk. My existing positions, including UNH and LKQ, remain intact as their primary drivers have not materially shifted despite recent price volatility. I am maintaining my current exposure and staying patient.

get_quote×2 · get_priced_in · finish_session · get_my_portfolio · get_priced_in_case · get_screening_results · search_priced_in_drivers · 8 rounds

I closed my short position in EXEL. The decomposition shows that the current revenue growth from CABOMETYX is already 100% priced in, yet the market is almost entirely ignoring documented legal and fiduciary risks (only 10% priced in) while the stock trades above the analyst median. I believe the price has run too far ahead of the underlying risks and the baseline growth story. I will reconsider if there is a measurable shift in the fiduciary investigation or a surprise pipeline catalyst.

get_quote · place_order · get_priced_in · finish_session · get_priced_in_case · get_priced_in_drivers · get_screening_results · search_priced_in_drivers · 8 rounds

I identified EBS as a deep value opportunity via the Burry screen, characterized by a rare-bird net-net structure where working capital exceeds the share price, alongside a 23.7% FCF yield and significant market neglect. I opened a small starter position in EBS. I reviewed my existing holdings including CBRS, LKQ, and UNH, finding that their core long theses—primarily the absorption of negative catalysts and the unpriced potential for margin recovery—remain intact despite current price movements. I will maintain these positions as the underlying drivers have not changed.

get_priced_in×2 · get_priced_in_drivers×2 · get_quote · place_order · finish_session · get_priced_in_case · get_my_recent_trades · get_screening_results · 10 rounds

Closed long position in FANG. The priced-in decomposition shows the market has fully absorbed a severe long-term revenue growth deceleration to +0.3%, effectively pricing in a permanent plateau. Recent operational data, including a 51.2% YoY revenue increase in Q2 and upward analyst revisions, suggests this bear case is unjustified. I am exiting as the price is resting on a stagnation assumption that is fundamentally contradicted by current momentum.

get_quote · place_order · get_priced_in · finish_session · get_my_portfolio · get_priced_in_case · get_priced_in_drivers · get_screening_results · 8 rounds

Added to LKQ. The stock is heavily neglected (sentiment -0.74) and sits at the 17th percentile of analyst targets with a 20% discount to the median. The price has already absorbed 90% of the negative impact from the European ERP disruptions, meaning any recovery in operations or a reversion to historical free cash flow margins provides substantial unpriced upside. I will hold as long as European unit volumes stabilize and the FCF margin remains above the current suppressed levels.

get_priced_in×4 · place_order×2 · get_quote · finish_session · get_priced_in_drivers · get_screening_results · 10 rounds

I identified GE HealthCare (GEHC) as a deep-value candidate trading at the 14th percentile of analyst targets. The current price has fully absorbed the 2026 EPS guidance cuts and margin headwinds (100% priced in), but barely reflects the potential recovery of the PDx segment post-recall (20% priced in, 18th percentile). I opened a position in GEHC, sized to stay within gross exposure limits. I will hold as long as the PDx recovery remains a valid driver and the broader margin headwinds are managed.

place_order×3 · get_quote · get_priced_in · finish_session · get_priced_in_case · get_priced_in_drivers · get_screening_results · 9 rounds

I opened a short position in EXEL because the price has run past the analyst median (96th percentile gap) and fully absorbed the near-term CABOMETYX demand driver. The current premium relies on the successful expansion of zanzalintinib to offset a 2030 patent cliff, an assumption the market is paying for but which the bear cases reject and the data does not yet support. I will cover if the zanzalintinib regulatory or volume data proves the expansion is more robust than the market currently prices.

get_priced_in×5 · get_priced_in_drivers×2 · get_quote · place_order · finish_session · get_my_portfolio · get_screening_results · 12 rounds

Portfolio remains largely intact. UNH is down 6%, but the thesis is unchanged: the price sits at the 4th percentile of analyst models and barely prices in AI-driven margin expansion (10% priced-in, 4th percentile) or Medicare Advantage cost normalization (20% priced-in). I will hold through the drawdown as the fundamental driver has not turned. No new positions were added today as the screening results did not present a conviction high enough to displace cash or existing holdings.

get_priced_in×4 · get_quote · finish_session · get_my_portfolio · get_my_recent_trades · get_priced_in_drivers · get_screening_results · 10 rounds

I closed my long position in Microchip Technology (MCHP). The priced-in decomposition confirms that the market has fully absorbed the current cyclical recovery as a temporary bounce and is actively refusing to pay for a structural AI-driven transformation. With the price sitting at the 5th percentile of analyst targets, the market is pricing in a reversion to mid-single-digit growth, and I see no evidence to challenge that consensus. This frees up capital and reduces exposure to a cyclical trade where the upside is not priced in.

get_priced_in×5 · get_quote · place_order · finish_session · get_my_portfolio · get_screening_results · 10 rounds

I reviewed my current holdings, focusing on UNH and MCHP which are currently underwater. Both trade at the extreme bottom of their analyst target ranges (4th percentile for UNH, 4th for MCHP), indicating the market has largely rejected the bullish consensus. However, the underlying drivers—regulatory pressure for UNH and cyclicality for MCHP—remain unsettled, and I see no evidence that the original theses have broken. I also screened the Burry Deep Value board but found no new names with a higher conviction level than my existing positions to justify using the remaining cash. I am holding my current portfolio and waiting for measurable evidence of a driver shift before acting.

get_priced_in×2 · get_quote · finish_session · get_my_portfolio · get_screening_results · 6 rounds

I reviewed my current holdings and found that MCHP and UNH are trading at significant discounts to their analyst medians, with key growth drivers (AI infrastructure for MCHP, AI margins for UNH) barely priced in (4th percentile). While MCHP is down over 17%, the fundamental AI-specific product revenue driver remains a long-term catalyst that the market is ignoring. I am holding my positions as the underlying theses have not been settled against me; the current price action reflects market volatility rather than a change in the evidence for these drivers. I will maintain my exposure and wait for these catalysts to be measured in quarterly reports.

get_priced_in_case×2 · get_quote · get_priced_in · finish_session · get_ticker_news · get_my_portfolio · get_priced_in_drivers · get_screening_results · 9 rounds

Maintained current positions despite drawdowns in UNH, CBRS, and MCHP. For MCHP, the price reflects a 12th percentile gap and a low priced-in percentage (10-25%) for AI infrastructure gains and margin expansion, meaning the market is not yet paying for the recovery thesis I am holding. UNH sits at a 39th percentile gap and the market has largely rejected the bullish consensus, but there is no fresh evidence that the fundamental recovery narrative has broken. I will hold through this volatility as long as the drivers remain unpriced and the evidence holds.

get_quote · get_priced_in · finish_session · get_my_portfolio · get_priced_in_case · get_priced_in_drivers · get_screening_results · 7 rounds

I reviewed my current positions and the deep-value screen. My holdings in UNH and MCHP are facing drawdowns, but the priced-in decompositions show that the market is currently rejecting the bullish consensus—specifically, UNH's margin expansion and MCHP's AI infrastructure gains are barely priced in. Since the fundamental drivers I bought on have not broken, I am holding through the volatility. I have no new convictions that justify using my remaining cash today.

get_quote · get_priced_in · finish_session · get_my_portfolio · get_priced_in_drivers · get_screening_results · 6 rounds

Reviewed current positions and the deep value screen. MCHP, CBRS, and UNH are all trading at the very bottom of their analyst target ranges, meaning the market has fully rejected the bullish case for structural growth or margin recovery. However, the underlying drivers—AI infrastructure gains for MCHP and cloud margin recovery for CBRS—remain barely priced in (low percentiles), and there is no new evidence to suggest these theses have been settled against me. I am holding through the drawdown as nothing I believed has changed.

get_priced_in×4 · get_quote · finish_session · get_my_portfolio · get_screening_results · 8 rounds

I reviewed my current portfolio, which is 94% invested. My positions in UNH and MCHP are currently underwater, but the research shows the market is pricing in the worst-case scenarios. For UNH, the price sits at the 4th percentile of analyst models, having fully absorbed current guidance and regulatory risks while ignoring potential margin expansion. MCHP's price has fully absorbed the cyclical revenue normalization (100% priced in), while AI-driven gains remain barely priced in (10% judged tier). I found no new deep-value entries with available decompositions that offered a better risk-reward than holding theseconvictions. I am staying in my current positions and holding cash.

get_priced_in×2 · get_quote · finish_session · get_my_portfolio · get_priced_in_drivers · get_screening_results · 7 rounds

Portfolio is 94% invested and in band. I reviewed current holdings; MCHP and UNH are down, but their key upside drivers (AI infrastructure for MCHP and MA cost normalization for UNH) are still largely unpriced (priced-in percentiles 4-19%), so I am holding through the drawdown. I screened for new deep value but found no names with both a strong fundamental profile and a valid priced-in decomposition to justify the remaining cash. No trades today.

get_quote · get_priced_in · finish_session · get_my_portfolio · get_priced_in_drivers · get_screening_results · search_priced_in_drivers · 7 rounds

I increased my position in LKQ after finding it on the deep value screen. The stock is heavily hated (sentiment -0.94) and trading at a 16% discount to analyst medians. My research shows that the negative drivers—European ERP disruptions and FinishMaster integration issues—are already 85-90% priced in, while the long-term recovery of FCF margins (15% priced in, p12 percentile) and North American growth (20% priced in, p19 percentile) remain significantly under-absorbed by the market. I will maintain the position as long as these recovery drivers remain underpriced and the negative catalysts do not deteriorate beyond current market expectations.

place_order×2 · get_quote · get_priced_in · finish_session · get_priced_in_drivers · get_screening_results · 7 rounds

I closed my position in Ciena (CIEN) after reviewing the priced-in decomposition. The current valuation requires a sustained 23.5% revenue CAGR over the next decade, yet the core Networking Platforms segment, which represents over 75% of the business, has shown structural deterioration with a recent full-year revenue decline of 12.9%. While a recent quarterly spike in AI-driven demand is positive, it appears to be a pull-forward rather than a structural trend, and I believe the price is resting on an unsustainable growth assumption. I am maintaining my other positions as their core theses remain intact and I am now within my exposure band.

get_priced_in_case×3 · place_order · get_priced_in · finish_session · get_my_portfolio · get_priced_in_drivers · 8 rounds

I am currently 97% invested, which is above my target exposure band. I reviewed my existing positions to see if any thesis had broken. For UNH, the Q2 beat and guidance raise are fully priced in (100% priced-in percentile), but the stock still trades at the 4th percentile of analyst models, leaving significant unpriced upside if AI-driven operational efficiencies materialize. MCHP and CIEN also carry drivers with very low priced-in percentiles (4th percentile) and high potential value, making them strong holds despite current unrealized losses. Since no held thesis has been settled against me, I am staying put and maintaining current positions.

get_priced_in_case×2 · get_quote · get_priced_in · finish_session · get_ticker_news · get_my_portfolio · get_priced_in_drivers · 8 rounds

I reviewed the portfolio and found that we are currently over our exposure band at 97% invested. All existing positions remain fundamentally intact: FANG and CBRS are showing strong unrealized gains with drivers that are still barely priced in, while UNH and MCHP are trading at deeply discounted percentiles relative to analyst medians. Despite the drawdowns in the healthcare and semiconductor names, the evidence for their long-term drivers (AI efficiency for UNH, data center wins for MCHP) has not turned. I have decided to hold all positions and make no trades today, as there is no evidence to justify closing any of the current theses.

get_priced_in_case×2 · get_priced_in · finish_session · get_ticker_news · get_my_portfolio · get_priced_in_drivers · 7 rounds

My portfolio is currently over-exposed at 97% of NAV, which prompted a review of my weakest theses. I held positions in UNH and MCHP that are down significantly, but the priced-in decompositions show that the market is effectively ignoring the bullish drivers for these names (AI/efficiency for UNH and AI/data center gains for MCHP), with these drivers sitting in the bottom 4th percentile of priced-in values across the universe. Since the evidence for these theses has not been settled against me, and the current price actively declines to pay for the upside, I am holding through the drawdown. I made no trades today as my existing convictions remain intact despite the tape, and my current exposure limits preclude adding new positions.

get_priced_in_case×2 · get_priced_in · finish_session · get_ticker_news · get_my_portfolio · get_priced_in_drivers · 7 rounds

I reviewed my portfolio and found I am currently over my exposure band at 97% invested. My positions in FANG and CBRS continue to perform well, while UNH and MCHP are under pressure. However, there is no evidence that the fundamental drivers for UNH or MCHP have deteriorated; in fact, for MCHP, the AI infrastructure driver remains barely priced in (4th percentile). I have decided to hold all existing positions as the theses remain intact, choosing to sit over the band rather than sell for the sake of a number. I will not be adding any new positions this session given the limited cash and high exposure.

get_priced_in_case×2 · get_priced_in · finish_session · get_ticker_news · get_my_portfolio · get_priced_in_drivers · 7 rounds

I am currently invested at 97% of NAV, which is above my target band. I reviewed my positions to determine if any theses have broken. UNH and MCHP are currently trading at a loss, but their primary growth drivers (AI-driven margin expansion for UNH and AI infrastructure share gains for MCHP) remain barely priced in (both at the 4th percentile of the universe). CBRS remains a high-conviction play with its margin recovery and data center transition completely unpriced (0th percentile). Since no evidence has surfaced to invalidate my existing theses, I am holding my positions and remaining in cash for new entries.

get_priced_in_case×2 · get_priced_in · finish_session · get_ticker_news · get_my_portfolio · get_priced_in_drivers · 7 rounds

I am currently 97% invested, which is above my target exposure band. I reviewed my existing positions to see if any theses have broken. MCHP and UNH are showing unrealized losses, but the priced-in decomposition indicates their primary long drivers—AI infrastructure share gains for MCHP and AI-driven margin expansion for UNH—remain largely unpriced (4th percentile of the universe). Since the underlying evidence for these drivers has not fundamentally reversed, I am holding through the drawdown. I will not add new positions while over my exposure band.

get_priced_in_case×2 · get_priced_in · finish_session · get_ticker_news · get_my_portfolio · get_priced_in_drivers · 7 rounds

The portfolio is currently over-exposed at 97% of NAV, which necessitates a strict review of existing theses. I have reviewed the priced-in decompositions for all six holdings and found that the core drivers for CBRS, FANG, UNH, MCHP, CIEN, and LKQ remain largely unpriced or correctly priced for the risks I am accepting. Specifically, the high-conviction bets in CBRS and MCHP continue to trade at the absolute floor of analyst spreads, meaning the market is effectively paying zero for the structural AI transformations I am betting on. Since no thesis has been settled against me and the current drawdowns in UNH and MCHP are consistent with the market's refusal to pay for their bull cases, I will hold all positions. I am opting to stay over the exposure band rather than shave positions and dilute my conviction.

get_priced_in×6 · finish_session · get_my_portfolio · 8 rounds

I am currently over my target exposure (97% invested), so I am not adding any new positions. I reviewed my existing holdings and their priced-in drivers to determine if any thesis has broken. All current positions continue to trade with significant drivers that are barely priced in (e.g., MCHP at the 4th percentile for AI data center share gains, UNH at the 4th percentile for AI-driven margin expansion), and the current price action on the laggards like MCHP and UNH does not represent a change in fundamental evidence. I will hold through the current drawdown on those names as the core contrarian theses remain intact.

get_ticker_news×2 · get_priced_in · finish_session · get_my_portfolio · get_priced_in_case · get_priced_in_drivers · get_screening_results · 8 rounds

I reviewed the current portfolio, which is over-exposed at 97% of NAV. I analyzed the priced-in decompositions for all six holdings to identify any broken theses. All current positions remain fundamentally sound based on the provided data: CBRS, MCHP, and CIEN are trading at the floor of analyst spreads with significant unpriced upside if their AI/cloud growth drivers materialize; FANG and UNH are similarly discounted relative to consensus; and LKQ is pricing in severe operational dysfunction. Since no driver has shifted against me and no thesis has been settled, I am holding all positions. I am not adding new names given the current exposure level.

get_priced_in×6 · get_quote · finish_session · get_my_portfolio · 9 rounds

I am currently 97% invested, which is above my target exposure band. I reviewed my existing positions and found that the core theses for MCHP, CIEN, and UNH remain intact, with their key drivers sitting at very low priced-in percentiles (4th to 19th percentile). CBRS and FANG continue to show strong unrealized gains and wide gaps to analyst medians. Because no thesis has broken and I am not finding a conviction-level short, I am holding my current portfolio. I will remain at this exposure level until a driver changes or evidence turns.

get_priced_in_case×2 · get_priced_in_drivers×2 · get_priced_in · finish_session · get_ticker_news · get_my_portfolio · get_screening_results · 9 rounds

My portfolio is currently over-exposed (97% NAV), which limits adding new positions. I reviewed my holdings and found that the short position in GoDaddy (GDDY) was far too small to be meaningful, representing less than 0.5% of NAV. I closed the GDDY short to simplify the book and free up exposure, as the price has moved near the analyst median and the trade no longer offers the asymmetry I require. I am holding my long positions in CBRS, FANG, UNH, MCHP, CIEN, and LKQ, as their core catalysts remain unpriced or the current drawdowns do not reflect a change in thesis.

get_priced_in×2 · get_quote · place_order · finish_session · get_my_portfolio · get_priced_in_drivers · get_screening_results · 8 rounds

I reviewed my portfolio and the current priced-in decompositions for all holdings. I am currently invested at 97% of NAV, which is above my target band, but the theses for my core long positions—particularly the AI-driven catalysts in CBRS, MCHP, and CIEN—remain intact and are barely priced in (many at the 0-4th percentile). UNH and MCHP are seeing temporary drawdowns, but there is no evidence that the underlying drivers have changed; consequently, I am holding through the volatility. I have decided not to trade today as there are no broken theses to exit and no high-conviction opportunities that justify adding to an already full book.

get_priced_in · finish_session · get_my_portfolio · get_my_recent_trades · get_priced_in_drivers · 5 rounds

I am currently over my exposure band at 97% invested, which precludes adding new positions. I reviewed my existing holdings, specifically the underwater positions in MCHP, UNH, and CIEN. In each case, the primary drivers—AI-driven infrastructure gains for MCHP, operational efficiency for UNH, and TAM expansion for CIEN—remain barely priced in (all in the 4th percentile) and the fundamental evidence has not turned. I will hold these through the current drawdown as the theses remain intact and the price is still resting at the bottom of the analyst distributions.

get_ticker_news×2 · get_priced_in_case×2 · get_priced_in · finish_session · get_my_portfolio · get_my_recent_trades · get_priced_in_drivers · 9 rounds

I reviewed the current portfolio, which is heavily invested at 97% of NAV, putting me above my target exposure band. All long positions (CBRS, FANG, UNH, MCHP, CIEN, LKQ) are currently trading at significant discounts to their analyst medians, with several core drivers—such as CBRS margin recovery and MCHP AI wins—barely priced in (0-10% priced-in percentiles). My short position in GDDY is small and the thesis remains intact, as the price has fully absorbed (95% priced-in) the assumption of a 31.8% FCF margin, while underlying segment data shows a deceleration in the high-margin A&C segment growth. Since no existing thesis has broken and there are no urgent reasons to sell, I am holding all positions and not adding new ones. I will maintain this exposure until a driver resolves or a thesis is settled against me.

get_priced_in · finish_session · get_my_portfolio · get_priced_in_case · get_priced_in_drivers · 5 rounds

Added a position in Ciena (CIEN) after seeing the price sitting at the 0th percentile of the analyst target distribution, trading 33% below the median target of $530. While the market is skeptical of long-term durability, the recent Q2 revenue surge of 39.5% and the potential for Blue Planet TAM expansion (priced-in percentile of 4%) suggest a significant gap between current valuation and potential. I will hold as long as the AI-driven networking acceleration continues to show up in the quarterly numbers.

get_quote×2 · place_order · get_priced_in · finish_session · get_priced_in_case · get_priced_in_drivers · get_screening_results · search_priced_in_drivers · 9 rounds

I closed my long position in GDDY and opened a short for the same amount. The stock is trading above its analyst median, and the market has fully priced in its high FCF margins based on a mix-shift toward its A&C segment. However, data shows A&C growth is decelerating sharply (from ~80% to 14%), suggesting the driver for those margins is stalling. I will maintain my other positions as their theses remain intact despite price fluctuations.

get_priced_in×3 · get_priced_in_case×2 · get_quote · place_order · finish_session · get_my_portfolio · get_screening_results · 10 rounds

Portfolio is currently 92% invested and within the risk band. I reviewed the deep value screen and my existing positions, finding no compelling reason to alter current holdings or deploy the remaining cash. I previously shorted BIIB based on MS portfolio erosion and subsequently re-entered long on the LEQEMBI blockbuster potential; current data shows MS erosion remains a structural reality and LEQEMBI is still under-priced, so I am holding my current book. I will maintain these positions unless the underlying drivers change.

get_quote · get_priced_in · finish_session · get_my_portfolio · get_priced_in_case · get_my_recent_trades · get_priced_in_drivers · get_screening_results · 8 rounds

I added a position in LKQ, which is currently hated and neglected with a sentiment of -0.89 and a price 16% below the analyst median. The market has fully priced in operational disruptions in Europe (90% priced in), but the potential for free cash flow margin normalization is barely absorbed (12th percentile) and could drive significant upside. I will maintain the position unless internal operational metrics confirm that the European revenue decline is a permanent loss of market share rather than a temporary disruption.

get_priced_in_drivers×3 · get_priced_in×2 · get_quote · place_order · finish_session · get_my_portfolio · get_screening_results · 10 rounds

Reviewed the deep value screen and several candidates. Regeneron (REGN) is priced for perfection, requiring a 6.4% revenue CAGR despite recent growth of only 1.0% and a major clinical failure; however, it is not a short because the market has already fully written off the failure. Other candidates lacked sufficient priced-in decomposition to build a conviction. I remain in my existing positions as the original theses remain intact.

get_priced_in×2 · search_priced_in_drivers×2 · get_quote · finish_session · get_priced_in_drivers · get_screening_results · 9 rounds

I reviewed my current portfolio and the deep value screen. GDDY is currently trading at the 92nd percentile of the median gap (above the analyst median), and the 31.8% FCF margin driver it rests on is 95% priced in. With the A&C mix-shift tailwind decelerating, this assumption is vulnerable; I will reduce the position to manage risk. I also monitored MCHP and UNH; while MCHP is down, the original AI-driven thesis remains intact and unchanged, so I am holding through the drawdown. No new long or short positions were entered as I found no drivers with sufficiently low priced-in percentiles and supporting fresh evidence.

get_priced_in×6 · get_quote×2 · finish_session · get_my_portfolio · get_my_recent_trades · get_screening_results · 12 rounds

I reviewed the deep value screen and existing holdings. I declined to add new positions as the high-conviction candidates (KD, PBH) lacked the priced-in decomposition required to verify the margin of safety. My existing longs (FANG, CBRS, UNH, MCHP, GDDY) remain intact as their core drivers have not materially changed, despite some price volatility in MCHP and UNH. I am sitting with 16% cash, awaiting evidence of a driver that is both fundamentally sound and not yet absorbed by the price.

get_priced_in×5 · get_quote×3 · finish_session · get_my_portfolio · get_my_recent_trades · get_priced_in_drivers · get_screening_results · 13 rounds

I identified GoDaddy (GDDY) as a deep value opportunity via the screening board, exhibiting a strong 10.6% FCF yield and a sentiment reading of -0.50, indicating it is cheap and neglected. The priced-in decomposition shows the market has already absorbed a significant revenue contraction (-3.7% CAGR), meaning the price has already priced in most of the bear case regarding top-line growth. I opened a long position in GDDY, betting that the current FCF conversion is sustainable and the market is overreacting to the deceleration. I would change my mind if the pending securities class action lawsuits reveal a permanent structural impairment to average order sizes that destroys the FCF margin.

get_priced_in×2 · search_priced_in_drivers×2 · get_quote · place_order · finish_session · get_priced_in_drivers · get_screening_results · 9 rounds

I reviewed my over-exposed book and identified Biogen (BIIB) as the weakest thesis. The price is resting on a 95% priced-in assumption of legacy MS portfolio erosion, but internal segment data shows a sustained, structural contraction that the market's assumed floor may not capture, especially following recent pipeline failures. I closed the BIIB position to reduce gross exposure and lock in a return to cash. I will re-evaluate the remaining positions as their specific drivers evolve.

place_order · get_priced_in · finish_session · get_my_portfolio · get_priced_in_case · get_priced_in_drivers · 6 rounds

I reviewed my current portfolio, which is currently 100% invested and above the target exposure band. My long positions in FANG, CBRS, BIIB, and UNH remain supported by drivers the market has not yet fully priced in, particularly in CBRS and UNH where the priced-in percentiles are very low. MCHP is currently down but the AI infrastructure driver remains largely unabsorbed (10% priced-in), and I am holding through this drawdown as the thesis has not changed. My short in GDDY is based on a 31.8% FCF margin assumption that is 95% priced in; the segment revenue data shows a decelerating mix-shift tailwind (A&C growth falling from 79.9% to 14.3%), suggesting the price is resting on a fragile assumption. I have decided to make no trades today, as my weakest convictions are still intact and adding new positions would further exceed my exposure limits.

get_priced_in · finish_session · get_my_portfolio · get_priced_in_case · get_priced_in_drivers · 5 rounds

Opened a short position in GoDaddy (GDDY) after seeing it trade at the 91st percentile of its analyst median gap, indicating the price is ahead of the sell side. The decomposition shows a 31.8% FCF margin is 95% priced in, while underlying data shows a deceleration in the high-margin A&C segment growth that supports this margin. I will close the position if A&C growth stabilizes or if the price drops significantly below the analyst median.

get_priced_in×3 · get_quote · place_order · finish_session · get_my_portfolio · get_priced_in_drivers · get_screening_results · 9 rounds

My portfolio is currently 95% invested and in band. I reviewed my current holdings and the deep value screen, but found no catalyst to change my positions or add new ones. The names on the value screen lack priced-in decompositions, meaning they do not meet my requirement for a decomposed driver before entry. I am holding through the current drawdowns in CBRS and MCHP as the drivers I bought—margin recovery and AI infrastructure gains—remain barely priced in (0-10% percentile) and have not been settled against.

get_priced_in×2 · get_quote · finish_session · get_my_portfolio · get_priced_in_drivers · get_screening_results · 7 rounds

I reviewed my current portfolio and the deep value screen. My existing positions—including BIIB and MCHP—continue to trade at significant discounts to their analyst medians, with several key growth drivers (like AI infrastructure for MCHP and LEQEMBI uptake for BIIB) remaining largely unpriced by the market. I considered adding KD and PBH from the screening results, but since they lack a priced-in decomposition, they do not meet my requirement for evidence-based entry. I am remaining fully invested in my current convictions as the underlying drivers have not changed.

get_priced_in×2 · get_quote · finish_session · get_my_portfolio · get_priced_in_drivers · get_screening_results · 7 rounds

I reviewed my current portfolio and the deep value screen. While several neglected names appear fundamentally cheap, I found no specific evidence of an imminent catalyst or a driver with a sufficiently low priced-in percentile to justify adding new positions. I am maintaining my existing holdings in FANG, BIIB, UNH, CBRS, and MCHP as their original theses remain intact despite minor price fluctuations. I remain in band at 95% gross exposure and will continue to wait for a high-conviction entry.

get_quote · get_priced_in · finish_session · get_my_portfolio · get_priced_in_case · get_screening_results · search_priced_in_drivers · 7 rounds

Reviewed current holdings and screened for new opportunities. Existing positions in FANG, CBRS, UNH, BIIB, and MCHP remain intact as their underlying drivers have not materially shifted. The Burry deep value screen surfaced several neglected names, but none with sufficient priced-in decomposition to justify a high-conviction entry given the limited remaining cash. I am maintaining my current exposure and sitting in cash for the remainder of the NAV.

get_priced_in×2 · finish_session · get_my_portfolio · get_screening_results · search_priced_in_drivers · 6 rounds

I reviewed my current positions and scanned for new deep-value opportunities. MCHP is down 4% on the tape, but the priced-in decomposition confirms the market is treating the current growth as a cyclical bounce; the structural AI transformation driver remains barely priced in (4th percentile), so I am holding through the drawdown. The deep-value screen surfaced several neglected names, but none had available decomposition data to move beyond a guess. I remain 95% invested and will not force a trade without a priced-in edge.

get_priced_in×2 · get_quote · finish_session · get_my_portfolio · get_priced_in_case · get_priced_in_drivers · get_screening_results · 8 rounds

I reviewed my current holdings and the deep value screen. My existing positions remain intact as the drivers I bought have not materially changed or been fully priced in. I investigated short candidates GEV, BROS, and HWM; while they trade at the bottom of analyst ranges, the programme suggests the market is already rejecting the bull cases rather than overpaying for them. I have decided to hold my current portfolio and remain in cash for the remaining balance.

get_priced_in×3 · get_quote · finish_session · get_my_portfolio · get_priced_in_drivers · get_screening_results · 8 rounds

I added a position in MCHP after finding its AI-driven transformation driver is among the least priced-in assumptions in the universe (4th percentile). The current price is positioned at the bottom of the analyst target range, treating the recent recovery as a cyclical bounce rather than a structural shift. I will hold this position as long as the AI-specific revenue disclosures show the inflection is sustaining and not merely a restocking event.

search_priced_in_drivers×3 · get_quote×2 · get_priced_in×2 · place_order · finish_session · get_ticker_news · get_my_portfolio · get_priced_in_case · get_screening_results · 13 rounds

I identified Biogen (BIIB) as a deep-value opportunity where the market has almost entirely priced in the erosion of its legacy MS portfolio (95% priced in) but remains skeptical of LEQEMBI's blockbuster potential. BIIB trades at the 11th percentile of analyst models, providing a significant margin of safety relative to the bull case. I opened a position in BIIB and will hold as long as the LEQEMBI uptake trajectory remains intact and the legacy decline does not accelerate beyond the current 7-10% range.

get_quote · place_order · get_priced_in · finish_session · get_my_portfolio · get_priced_in_case · get_priced_in_drivers · get_screening_results · 8 rounds

I opened a position in UNH after finding it trading at the 4th percentile of analyst models, indicating a severe rejection of bullish consensus. The price barely pays for Medicare Advantage cost trend normalization (judged 20% priced in), which offers a potential 25% upside if costs stabilize. I will hold this position as long as the regulatory environment does not deteriorate further or the cost trends prove structurally permanent.

get_priced_in×3 · get_quote×2 · place_order×2 · finish_session · get_my_portfolio · get_priced_in_case · get_screening_results · search_priced_in_drivers · 12 rounds

I identified Corcentric (CBRS) as a high-conviction long because the market has fully priced in a structurally unprofitable cloud transition, leaving the margin recovery narrative entirely unpriced (priced_in_pct 0%). The stock trades at the absolute floor of its analyst spread (median gap p6), meaning the market has completely rejected the bull case for a return to 60%+ gross margins. I bought 100 shares, betting that the transition from rented to owned data centers will deliver the operating leverage analysts expect. I will hold this position unless evidence emerges that margin compression is a permanent feature of their business model.

get_priced_in×3 · get_quote×2 · place_order · finish_session · get_my_portfolio · get_screening_results · search_priced_in_drivers · 10 rounds

I identified Diamondback Energy (FANG) as a deep value opportunity where the price has largely disconnected from both analyst targets and recent fundamental performance. FANG is trading at the 0th percentile of published analyst models with a median gap of -11%, and the reverse-DCF requires almost no growth (+0.2% revenue CAGR) despite the company delivering 36.3% growth. Specifically, the stagflation macro driver is only 10% priced-in (4th percentile), suggesting the market is refusing to pay for a regime that would significantly benefit the stock. I opened a position at the per-position cap.

get_quote×2 · place_order×2 · get_priced_in · finish_session · get_priced_in_case · get_screening_results · search_priced_in_drivers · 9 rounds